Navigation Links
Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
Date:10/11/2010

s?key=PFAUVPB9C">https://www.theconferencingservice.com/prereg/key.process?key=PFAUVPB9C.  A replay of the call will be available for two weeks following the event.

To access the live conference call via phone, dial 888-713-4217. International callers may access the live call by dialing 617-213-4869.  The reference number to enter the call is 20601442.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers.  The reference number for the replay of the call is 36572489.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application in December 2009.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commerci
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- MHG ... provider, has launched its Medical Equipment and ...  These services are tailored to the cruise industry,s ... prompted industry operators to propose that they should ... Medical,s new program is intended to create standardized ...
(Date:7/29/2014)... July 29, 2014 According to ... "Orthopedic Trauma Fixation Devices Market - Global Forecast, Market ... the global orthopedic trauma fixation devices market is estimated ... to grow at a CAGR of 7.2% from 2014 ... 9.3 billion in 2020. Browse the Orthopedic ...
(Date:7/29/2014)... LAKE CITY and ... -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an ... in the development of improved novel formulations ... active molecules announces expansion of its pharmaceutical ... new development direction includes large molecule drugs that ...
Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... 13, 2011 CVS Caremark Corporation (NYSE: ... president and chief financial officer of CVS Caremark, will ... 2011 Global Consumer Conference on June 22, 2011. Mr. ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) An ...
... 13, 2011 AmbiCom Holdings, Inc. (OTCQB: ABHI), a ... equipment suppliers, today announced that it has signed an ... Technology, Inc. ("ATI") subsidiary and E-Care Technology Corporation, ("ECT") ... runs for a period of three years. ...
Cached Medicine Technology:CVS Caremark to Present at the Jefferies 2011 Global Consumer Conference 2AmbiCom Forms Joint Alliance With E-Care Technology Corporation 2AmbiCom Forms Joint Alliance With E-Care Technology Corporation 3
(Date:7/29/2014)... Randy Dotinga ... News) -- When most children take on a task, ... of this neuro-boosting activity in kids with autism, according ... more severe symptoms of autism displayed even less of ... ,"This reduced flexibility often causes difficulty when children with ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Board of ... Holland & Hart LLP ’s Connie Akridge to ... currently serves as President of the Foundation. Akridge served as ... Akridge is a partner at Holland & Hart in Las ... and regulatory/administrative matters to insurance and healthcare clients for more ...
(Date:7/29/2014)... Washington D.C. (PRWEB) July 29, 2014 ... spending in Medicare Part D by a projected $2.9 ... report by the actuarial firm Milliman released today by ... average Part D premiums could increase by as much ... high-priced hepatitis C drugs, including Sovaldi and Olysio. , ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Law Offices ... Stepping Stones of Hope, a non-profit organization providing grief camps ... hand the anguish and suffering our clients experience from the ... desire to support an organization like Stepping Stones of Hope, ... grief. , Stepping Stones of Hope also includes a monthly ...
(Date:7/29/2014)... record the severity and regularity of their pain is ... , A new approach to the treatment of headaches, ... and is being led by Professor Paul Martin from ... He has developed an approach designed to enable people ... Learning to Cope with Triggers (LCT). , Using a ...
Breaking Medicine News(10 mins):Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2
... ALEXANDRIA, Va., Oct. 8 The National,Community Pharmacists ... two-term incumbent representing Illinois, for re-election to the,U.S. ... CEO of NCPA,issued the following statement:, "Senator ... and,America,s community pharmacies and the patients they serve. ...
... Pharmacists Association (NCPA) is endorsing Sen. Gordon Smith,(R-OR), ... the,U.S. Senate. Bruce Roberts, RPh, executive vice president ... "Senator Gordon Smith is a powerful advocate for ... serve. That is why the National,Community Pharmacists Association ...
... Inc. (OTCPK:,SNDY) is pleased to announce that the Company ... ending June 30, 2008. Revenues,generated through the first six-months ... comparable period in 2007. The Company,saw an increase in ... just,over $8,000 at the end of fiscal year 2007., ...
... are no safe substitutes for authentic,FDA approved injectables, ... and counterfeit cosmetic injectables are a threat to ... for Injectable Safety. "The,growing acceptance of cosmetic injections ... with consumer cautions," says Coalition,leader, plastic surgeon Jeffrey ...
... Extreme heat events (EHE), or heat waves, are the ... United States, responsible for more deaths annually than hurricanes, ... other climate-related changes in the worldwide environment that directly ... of the American Journal of Preventive Medicine . ...
... Kong Celebrates a Wealth of Innovative Products, HONG ... leader in,research and development, announces today that it will ... 2008 at Gordon Wu Hall, B P,International House to ... in 1902 in Minnesota, United States, 3M has an ...
Cached Medicine News:Health News:Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com 2Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Climate change will affect public health -- a call to action 2Health News:Climate change will affect public health -- a call to action 3Health News:3M Innovation Day 2Health News:3M Innovation Day 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
Medicine Products: